At Avid, a wholly owned subsidiary of Eli Lilly and Company, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an outstanding management team with extensive imaging and CNS development experience to help make pre-symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of challenging conditions such as Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease and Diabetes Mellitus. This may be possible because our molecular imaging compounds may be able to detect the first stages of pathological change; allowing early treatment and management of people at risk - perhaps before before symptoms of disease can develop.

Health Care

Life Sciences

Therapeutics

Avid Radiopharmaceuticals

Daniel M Skovronsky

Marybeth Devine

Amanda Morris

Robert Morrison

Kelly Conway

Carey Horchler

Anne McGeehan

Lisaann Trembath

David Wilson

Luckens Osias

Ian Halvorsen

Christine Gallagher

Caitlin Pearson

The Leadership Team at Avid Radiopharmaceuticals is responsible for steering the strategic direction of the company, focusing on the development and commercialization of innovative molecular imaging agents. Comprising top executives with extensive experience in imaging and CNS development, the team fosters collaboration and drives operational excellence to enhance early detection and treatment of chronic diseases such as Alzheimer's and Parkinson's. Their collective expertise ensures that Avid remains at the forefront of advancing medical imaging technology, ultimately aiming to improve patient outcomes.

Leadership Team

Operations and Support

Research and Development

Clinical Operations and Management

Leadership Team

About

Team members

Other teams at Avid Radiopharmaceuticals

Operations and Support

Research and Development

Clinical Operations and Management